Your shopping basket is empty.

Research

Fight Bladder Cancer supports evidence based medicine for all those affected by bladder cancer

Our research team

The Fight Bladder Cancer Research Division is currently working to progress the Fight Bladder Cancer Exemplar Study, develop further patient experience surveys and support Fight Bladder Cancer's involvement in ongoing clinical trials.

Clinical trials

A clinical trial is something that can be offered at any part in the bladder cancer journey, from initial suspected diagnosis, through investigations and different treatment, and in later follow up, or at end of life.

A clinical trial is not just something to “look at when all else fails”. 

There are a number of clinical trials in bladder cancer. These usually compare a new treatment which has the potential of working better or with less side effects, with what is used as the “gold-standard”.

Different trials are available in different hospitals. This is because of either the complexity of the trial or because of the type of treatment or test involved. For example, studies of surgery (cystectomy) or radiotherapy may only be open at the particular hospital or cancer centres where the operation or the radiotherapy takes place. All studies have particular tick boxes to confirm whether this study is the correct one for you and your cancer. It may be that you and your type of bladder cancer do not match what we call the eligibility criteria (or check list) for the study.

Remember that you should ask your doctor if you are suitable for a clinical trial, and it is always helpful to take information with you for any trials that your doctor may not be familiar with. If the study is open elsewhere in the UK and it looks as though you may be eligible for this (and are prepared to travel), you could ask your doctor to refer you. 

We campaign for a number of areas of research that are essential and long overdue, to give patients better survival and quality of life. 

Current Open Bladder Cancer Trials

Suspected bladder cancer

IDENTIFY

Hospitals often have a 'blanket' approach for investigating people with blood in their wee. IDENTIFY will collect data on people having these tests across the UK and internationally, looking at any trends with an aim to create a personalised diagnostic approach for each person. The data will give patients the ability to make informed decisions, as well as reducing unnecessary and potentially harmful tests. 
ClinicalTrials.gov ID: NCT03548688

Urox Biomarker

This trial will need a urine sample from participants who are under investigation for possible bladder cancer and are due to undergo a standard of care investigative cystoscopy and biopsy. This study is testing to see whether the UroX biomarker can be detected in urine samples and therefore be a way of diagnosing patients. Both healthy and bladder cancer participants are needed. 

ClinicalTrials.gov ID: NCT03973307


Newly detected or recurrent bladder cancer

ANTICIPATE X

After being diagnosed with bladder cancer, patients will be asked to provide a urine sample. The urine samples will be used to develop better ways of diagnosing bladder cancer in the future. 
ClinicalTrials.gov ID: NCT03664258


Non-invasive bladder cancer

PemBla

This study is for people with non-muscle invasive bladder cancer. Patients will receive a drug called pembrolizumab. This is an early study looking at the safety and ideal dose of this drug. 
ClinicalTrials.gov ID: NCT03167151

KEYNOTE-676

This study is for people who have high-risk non-muscle invasive bladder cancer that is persistent or recurrent following BCG induction. Patients will receive a drug called pembrolizumab along with BCG, or BCG without pembrolizumab. This is a study looking at how well pembrolizumab works together with BCG in people with bladder cancer.
ClinicalTrials.gov ID: NCT03711032

POTOMAC

This study is for people with non-muscle invasive bladder cancer. Patients will receive BCG treatment, with the possible addition of durvalumab. This is a study looking at how well durvalumab works in people with non-muscle invasive bladder cancer. 
ClinicalTrials.gov ID: NCT03528694

CheckMate 9UT

This study is for people with non-muscle invasive bladder cancer. Patients will receive nivolumab treatment, with the possible addition of BCG, BMS-986205, or BMS-986205 + BCG. This is a study looking at how well these treatments work in people with non-muscle invasive bladder cancer. 
ClinicalTrials.gov ID: NCT03519256

NCT03091764

This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side-effects. The symptom index will provide a method for assessing treatments from the patients’ perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer. 
ClinicalTrials.gov ID: NCT03091764

iROC

This study is for people with non-muscle invasive bladder cancer or muscle invasive bladder cancer who are going to have their bladders removed. Patients will have either robotically assisted bladder removal surgery, or open bladder removal surgery. The study will look at which type of surgery has a better number of days out of hospital, recovery and return to normal activities. 
ClinicalTrials.gov ID: NCT03049410


Advanced or metastatic bladder cancer

PLUMMB

This is for people with invasive bladder cancer. Patients will receive a drug called pembrolizumab in combination with radiotherapy. This is an early study looking at the safety, tolerability and effectiveness of combining pembrolizumab with radiotherapy.
ClinicalTrials.gov ID: NCT02560636

BladderPath

This study is to redesign the management pathway for patients with muscle-invasive bladder cancer by using an MRI scan rather than doing a transurethral resection of a bladder tumour (TURBT), to diagnose and more accurately and rapidly stage their cancer. We hypothesise this may improve outcomes for these patients by reducing the time from diagnosis to definitive treatment. isrctn.com 
International Standard Randomised Controlled Trial Number: ISRCTN35296862

PIVOT-02

This study is for people who have advanced or metastatic bladder cancer.  Patients will receive drugs called nivolumab and NKTR-214, and perhaps another drug called ipilimumab. This is an early study looking at the safety and ideal doses of the drugs. 
ClinicalTrials.gov ID: NCT02983045

NCT03170960

This study is for people who have locally advanced or metastatic bladder cancer. Patients will receive a drug called atezolizumab in combination with a new drug called cabozantinib. This is a very early study looking at the safety and ideal dose of cabozantinib.
ClinicalTrials.gov ID: NCT03170960

NCT03289962

This study is for people who have locally advanced or metastatic bladder cancer. Patients will receive a personalised cancer vaccine called RO7198457, with the possible addition of a drug called atezolizumab. This is an early study looking at the safety and ideal doses of the drugs. 
ClinicalTrials.gov ID: NCT03289962

NCT02599324

This is a study for people with advanced bladder cancer. Patients will receive chemotherapy (paclitaxel), along with a new drug called pemigatinib. This is a very early study looking at the safety of the drug and what is the ideal dose. ClinicalTrials.gov ID: NCT02599324

KEYNOTE-905

This study is for people who have muscle-invasive bladder cancer, and who are not eligible for chemotherapy. Patients will receive a drug called pembrolizumab along with radical cystectomy + pelvic lymph node dissection, or radical cystectomy + pelvic lymph node dissection without pembrolizumab. This is a study looking at how well pembrolizumab works together with surgery in people with bladder cancer. 

ClinicalTrials.gov ID: NCT03924895

KEYNOTE-866

This study is for people who have muscle-invasive bladder cancer. Patients will receive a drug called pembrolizumab along with chemotherapy and bladder removal, or chemotherapy and bladder removal without pembrolizumab. This is a study looking at how well pembrolizumab works together with chemotherapy and surgery in people with bladder cancer. 

ClinicalTrials.gov ID: NCT03924856

NCT03473743

This is a study for people with metastatic or inoperable bladder cancer who test positive for the FGFR (Fibroblast Growth Factor Receptor) alteration biomarker. This study will be used to test the ideal dose of two drugs called erdafitinib and cetrelimab, as well as to test their safety and how well they work.

ClinicalTrials.gov ID: NCT03473743 

NCT03390504

This is a study for people with advanced bladder cancer who test positive for the FGFR (Fibroblast Growth Factor Receptor) alteration biomarker. Patients will receive either chemotherapy, a drug called erdafitinib, or a drug called pembrolizumab. This study will test how well these drugs work in people with bladder cancer. 
ClinicalTrials.gov ID: NCT03390504 

FIGHT-201

This is a study for people with metastatic or inoperable bladder cancer who test positive for one of the FGF/FGFR biomarkers. Patients will receive a drug called pemigatinib. This is a very early study looking at the safety and ideal dose of the drug. 
ClinicalTrials.gov ID: NCT02872714

FIDES-02

This is a study for people with advanced bladder cancer who test positive for the FGFR (Fibroblast Growth Factor Receptor) biomarker. Patients will receive either a drug called derazantinib, or both derazantinib and another drug called atezolizumab. This is a very early study looking at the safety and ideal dose of derazantinib.
ClinicalTrials.gov ID: NCT04045613

JAVELIN Medley

This is a study for people with locally advanced or metastatic bladder cancer. Patients receive a drug called avelumab, with the possible addition of the drugs PF-04518600, PD 0360324, or PF-05082566 + PF-04518600. This is a study looking at how well these drugs work to treat people with bladder cancer. 
ClinicalTrials.gov ID: NCT02554812

NCT03317496

This is a study for people with locally advanced or metastatic bladder cancer. Patients receive best supportive care with the addition of a drug called avelumab. This is a study looking at the safety of avelumab, as well as how well avelumab works to treat people with bladder cancer. 
ClinicalTrials.gov ID: NCT03317496

NCT03317496

This is a study for people with locally advanced or metastatic bladder cancer. Patients receive chemotherapy with the addition of a drug called avelumab. This is a study looking at the safety of avelumab, as well as how well avelumab works to treat people with bladder cancer.
ClinicalTrials.gov ID: NCT03317496

NCT03523572

This study is for people who have advanced or metastatic bladder cancer, and who test positive for the HER2 biomarker. Patients will receive drugs called nivolumab and DS-8201a. This is an early study looking at the safety and ideal doses of the drugs.
ClinicalTrials.gov ID: NCT03523572

LEAP-011

This study is for people who have advanced or metastatic bladder cancer, and who either test positive for the PD-L1 biomarker or who are not eligible for chemotherapy. Patients will receive a drug called pembrolizumab, and perhaps another drug called lenvatinib. This is a study looking at how well these drugs work together in people with bladder cancer.
ClinicalTrials.gov ID: NCT03898180

NCT03782207

This study is for people who have advanced or metastatic bladder cancer, who have been previously treated with chemotherapy. Patients will receive a drug called atezolizumab. This is a study looking at how well this drug works in people with bladder cancer.
ClinicalTrials.gov ID: NCT03782207 

MORPHEUS mUC

For people who have advanced or metastatic bladder cancer, who have progressed during or following chemotherapy. Patients will receive a drug called atezolizumab, and perhaps one of the following drugs: enfortumab vedotin, niraparib, Hu5F9-G4, isatuximab, linagliptin, or tocilizumab.

ClinicalTrials.gov ID: NCT03869190

NCT03096054

For people who have advanced or metastatic bladder cancer. Patients will receive a drug called LY3143921. This is an early study looking at the safety and ideal doses of the drug.
ClinicalTrials.gov ID: NCT03096054

NCT03049410

Trial to compare robotically assisted radical cystectomy with open radical cystectomy. This is for people with non-muscle invasive bladder cancer or muscle invasive bladder cancer who will be having a radical cystectomy for treatment. This trial will compare robotically assisted radical cystectomy with open radical cystectomy. Patients will be randomised 1:1 to either have an robotically assisted radical cystectomy or open radical cystectomy and will be followed for 90 days following the treatment. 

ClinicalTrials.gov ID: NCT03049410

PIVOT-10

This study will look at the anti-tumour activity of the drug bempegaldesleukin along with nivolumab. The trial is for patients with cisplatin ineligible, locally advanced or metastatic urothelial cancers. It is a phase 2 clinical trial. Patients must not have had systemic chemotherapy or investigational agent for inoperable locally advanced or muscle invasive bladder cancer.  

ClinicalTrials.gov ID: NCT03785925

NCT03767348

This study is looking at the drug RP1 alone and then RP1 in combination with nivolumab. This trial needs participants with advanced and/or refractory solid tumours. The is a phase 1 and phase 2 trial and is being done to determine the maximum tolerated dose and recommended phase 2 dose of the drug. It is for a range of cancers but includes bladder cancer. 

ClinicalTrials.gov ID: NCT03767348

NCT03732677

This study is for people with muscle invasive bladder cancer. Its aim is to determine the efficiency and safety of Durvalumab in combination with Gemcitabine/Cisplatin. It is a phase 3 clinical trial and will use the drugs durvalumab, cisplatin and gemcitabine. Patients must be planning to undergo a radical cystectomy to be eligible. 

ClinicalTrials.gov ID: NCT03732677

NCT03661320

This is for people with muscle invasive bladder cancer. This study is looking at the use of the drug nivolumab with chemotherapy or nivolumab and BMS-986205 (another drug) with chemotherapy followed by continued immune-oncology therapy and comparing it to just chemotherapy. It will look at the success of the addition of the drugs. 

ClinicalTrials.gov ID: NCT03661320

NCT04316689

This study will look at the safety and tolerability of the drug S-588210 in people with unresectable recurrent and/or metastatic solid tumours. This trial is for multiple different cancers, but includes bladder cancer.  Participants will receive injections once a week for four weeks and then biweekly for 8 weeks of the new drug. 

ClinicalTrials.gov ID: NCT04316689

NCT03934827

This study is looking at the safety and tolerability of the drug MRx0518 in people with solid tumours at 30 days post-surgery. It is a phase 1 clinical trial and the trial will look at the drugs' anti-cancer and immune system modulating properties. Patients will need to be amenable to surgical resection. 

ClinicalTrials.gov ID: NCT03934827

Find out more about how we can support trials & research.

Please contact us direct for any further information requirements on 01844 351621 or use the contact form below or email us direct at info@fightbladdercancer.co.uk 

Research & Fight Bladder Cancer

To see a full set of our downloads please see our Downloads page.

Get in touch

We’ve done everything we can to make all the information on this site as accurate as possible. Whilst we have had support from a small team of medical professionals advisors to review the general medical content of this site, please remember, that only YOUR medical team can give YOU specific advice about YOUR symptoms or illness. We encourage you to discuss any potential options with them.